Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam

Japanese encephalitis

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Safety Surveillance After Immunization With IXIARO Postmarketing Surveillance Study for IMOJEV® in Republic of Korea A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX Flavivirus Cross-priming Potential of IMOJEV Safety and Immunogenicity of JECEVAX in Young Children Post-licensure Safety Study of IMOJEV® in Thailand This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Safety of Vero Cell – Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2